Who is sponsoring NCT03537521?

NCT03537521 is sponsored by Cardioangiologisches Centrum Bethanien.

What drugs are being tested in NCT03537521?

Interventions in NCT03537521: Urgent surgery which can not be postponed to the next 24 hrs.

What condition does NCT03537521 study?

NCT03537521 studies Severe Bleeding, Urgent Surgery.

Is NCT03537521 still recruiting?

NCT03537521 is currently withdrawn. Last updated 15 July 2020.

Last reviewed 2020-07-15 · How we verify

NCT03537521

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prospective, Observational, Non-interventional Open-Label, International, Multicenter Registry Regarding the Management of Severe Bleeding and/or Urgent Interventions During Treatment With Direct Oral Anticoagulants or Vitamin K Antagonists

Withdrawn Last updated 15 July 2020

What this trial tests

trial testing Urgent surgery which can not be postponed to the next 24 hrs in Severe Bleeding. Withdrawn.

Timeline

1 April 2020

Primary endpoint
1 April 2022

1 April 2023

Quick facts

Lead sponsor	Cardioangiologisches Centrum Bethanien
Status	Withdrawn
Study type	OBSERVATIONAL
Start date	1 April 2020
Primary completion	1 April 2022
Estimated completion	1 April 2023

Drugs / interventions tested

Urgent surgery which can not be postponed to the next 24 hrs

Conditions studied

Severe Bleeding — all drugs for Severe Bleeding →
Urgent Surgery — all drugs for Urgent Surgery →

Sponsor

Cardioangiologisches Centrum Bethanien

Who can join

Adults 18 to 99, any sex, with Severe Bleeding or Urgent Surgery. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

In hospital mortality up to 30 days after admission
Time frame: up to 30 days after hospital admission
Death rate (number of deaths)

Sponsor's own description

Patients treated with Vitamin K antagonists (VKA) or direct oral anticoagulants as Rivaroxaban, Apixaban, Edoxaban or Dabigatran, who experience severe bleeding and/or need urgent interventions/operations that cannot wait are included in this registry, or during emergency operations

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Cardioangiologisches Centrum Bethanien trials

Trials by the same sponsor.

NCT07390214 — REFOCUS-AF - "RepEat Ablation With AFFERA vs. COntact Force-Guided RF Catheters for Optimal OUtcomes in Symptomatic AF". · NA · recruiting
NCT07459387 — REal-world Valued Outcomes of a noveL Balloon-in-basket pUlsed Field ablaTION Catheter for Atrial Fibrillation RegistrY · NA · recruiting
NCT06403527 — Ultrasound Guyded Venous Puncture for Safe AF Ablation Procedures · NA · terminated
NCT07385417 — Electroporation Treatment for Early AF Management in Heart Failure With Preserved Ejection Fraction (HFpEF) Pilot Study · NA · recruiting
NCT05313048 — Prospective Observational Study to Evaluate a Possible Change in APS Antibody Profiles After COVID-19 Infection or Vacci · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03537521 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cardioangiologisches Centrum Bethanien
Last refreshed: 15 July 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03537521.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing